pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
HOFFMANN-LA ROCHE clinical programs — 58 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 286
- Drugs
- 212
- Patents
- 0
HOFFMANN-LA ROCHE projects
58 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.
HOFFMANN-LA ROCHE has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
WN45319
Hoffmann-La Roche
Multiple Sclerosis (MS)
1 trial -
WO39613
Hoffmann-La Roche
Urothelial carcinoma (UC)
1 trial -
WO42758
Hoffmann-La Roche
Metastatic Colorectal Cancer
1 trial -
WP43295
Hoffmann-La Roche
BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases
1 trial -
XO45189
Hoffmann-La Roche
HER2-positive advanced solid tumours
1 trial -
YO45758
Hoffmann-La Roche
Advanced Solid Tumors Harboring RAS Mutation(S)
1 trial -
atorvastatin
Hoffmann-La Roche
Healthy Volunteer
1 trial -
balapiravir [RO4588161]
Hoffmann-La Roche
Dengue
1 trial -
danoprevir
Hoffmann-La Roche
Healthy Volunteer
1 trial -
trastuzumab [Herceptin]
Hoffmann-La Roche
Healthy Volunteer
1 trial
Frequently asked questions
How many clinical projects does HOFFMANN-LA ROCHE have?
58 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.